TTD | Drug: D07NFW

Drug General Information
Drug ID	D07NFW
Former ID	DNC008009
Drug Name	BMS-196085
Drug Type	Small molecular drug
Indication	Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1]		Phase 1	[526197]
Formula	C24H26F2N2O5S
Canonical SMILES	CS(=O)(=O)NC1=C(C=CC(=C1)C(CNC(CC2=CC=CC=C2)C3=CC=C(C=C<br />3)OC(F)F)O)O
InChI	1S/C24H26F2N2O5S/c1-34(31,32)28-21-14-18(9-12-22(21)29)23(30)15-27-20(13-16-5-3-2-4-6-16)17-7-10-19(11-8-17)33-24(25)26/h2-12,14,20,23-24,27-30H,13,15H2,1H3/t20-,23+/m1/s1
InChIKey	XWLVOJZVWRCRMD-OFNKIYASSA-N
PubChem Compound ID	9870286
Target and Pathway
Target(s)	Beta-3 adrenergic receptor	Target Info	Inhibitor	[528868]
KEGG Pathway	Calcium signaling pathway
	cGMP-PKG signaling pathway
	Neuroactive ligand-receptor interaction
	Endocytosis
	Salivary secretion
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
PANTHER Pathway	Beta3 adrenergic receptor signaling pathway
Reactome	Adrenoceptors
Reactome	G alpha (s) signalling events
WikiPathways	Monoamine GPCRs
	Calcium Regulation in the Cardiac Cell
	GPCRs, Class A Rhodopsin-like
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 526197	BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptor. Bioorg Med Chem Lett. 2001 Dec 3;11(23):3041-4.
Ref 528868	Bioorg Med Chem Lett. 2007 Aug 1;17(15):4290-6. Epub 2007 May 16.Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.

Drug Information